Ash A. Alizadeh

Palo Alto University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

90h-index74.8kcitations597works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(204), Lymphoma Diagnosis and Treatment(168), Lung Cancer Treatments and Mutations(91), CAR-T cell therapy research(79), Chronic Lymphocytic Leukemia Research(46)

Publications597 total

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma
Journal of Clinical Oncology·2025· 1 citedOpen Access
Supplementary Tables S1-S15 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
2025Open Access
Supplementary Methods & Figures S1-S5 from Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors
2025Open Access
Optimizing First-Line Therapy for Diffuse Large B-Cell Lymphoma
Journal of the National Comprehensive Cancer Network·2025
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis
Blood·2025Open Access
Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas
Blood·2025Open Access
Multimodal discovery of distinct tumor ecosystems for classic Hodgkin lymphoma
Blood·2025Open Access
Non-invasive classification & molecular subtyping of mature lymphoid neoplasms by cell-free DNA profiling
Blood·2025Open Access
Molecular determinants of therapeutic response to nivolumab in Relapsed/Refractory PTCL: An integrated multiomic study of A phase II investigator-initiated trial
Blood·2025Open Access
Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma
Blood·2025Open Access
Non-invasive Mantle Cell Lymphoma risk stratification by inference of tumor proliferation from cfDNA
Blood·2025Open Access
Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study
Blood·2025Open Access
Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling
Blood·2025Open Access
Tracing malignant precursor mutations and their cellular origins in blood and bone marrow of primary central nervous system lymphomas by ultrasensitive genomic profiling
Blood·2025Open Access
A unified spatial & molecular atlas of anatomically restricted large B-cell lymphomas defines stereotyped cell ecosytems
Blood·2025Open Access
A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma
Blood Cancer Discovery·2025Open Access
CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias
2025Open Access
MA03.01 Ultrasensitive MRD Improves Detection in Resectable Stage I NSCLC
Journal of Thoracic Oncology·2025· 1 cited
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma
Nature Communications·2025Open Access
Treatment Kinetics and Local Response during and after Bridging Radiotherapy prior to CAR-T Cell Therapy for Lymphomas
International Journal of Radiation Oncology*Biology*Physics·2025
page 1 of 30Next →

Frequent Co-authors

Maximilian Diehn(26), Chih Long Liu(22), Aaron M. Newman(17), Andrew J. Gentles(12), Ronald Levy(11), Henning Stehr(11), Patrick O. Brown(10), Mohammad Shahrokh Esfahani(10), David M. Kurtz(10), Jacob J. Chabon(10), Florian Scherer(8), Joel W. Neal(7), Heather A. Wakelee(7), David Botstein(7), Robert B. West(6), Billy W. Loo(6), Ravindra Majeti(6), Mark P. Chao(6), Irving L. Weissman(6), Louis M. Staudt(5)